Search results
Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates
Zacks via Yahoo Finance· 2 days agoIovance (IOVA) reports mixed first-quarter results. Shares gain on encouraging initial demand for...
Massive study identifies new biomarkers for renal cancer subtypes, improving diagnosis and—...
Newswise· 7 days agoA new study led by University of Michigan Health Rogel Cancer Center researchers identifies novel...
New PET agent provides same-day imaging for clear cell renal cell carcinoma patients
Medical Xpress· 5 days agoA novel investigational PET imaging agent can rapidly and accurately visualize lesions in clear cell renal cell cancer (ccRCC) patients according to new research published in the May issue of ...
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
Motley Fool via Yahoo Finance· 6 hours agoExelixis Exelixis specializes in cancer medicines. It earned quite a reputation thanks to its most...
Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 6 days agoInvestors' focus will likely be on Iovance's (IOVA) progress with its ongoing commercial launch for...
Wedbush Boosts Janux Therapeutics (NASDAQ:JANX) Price Target to $74.00
ETF DAILY NEWS· 2 days agoJanux Therapeutics (NASDAQ:JANX – Free Report) had its target price increased by Wedbush from $53.00 to $74.00 in a research note published on Wednesday morning, Marketbeat reports. The brokerage ...
AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 5 days agoWe'd also like to congratulate ArsenalBio, who in April announced the first patient dosed in a Phase...
Fighting Cancer: A Basic Guide To Checkpoint Inhibitors
Forbes· 7 days agoThis article is part of an ongoing series on novel cancer advances, including immunotherapies such...
Good to Know: Grim diagnosis spurs Kent couple to sell possessions, plan RV trip of a lifetime
Akron Beacon Journal via Yahoo News· 7 days agoBut a scan last summer found new growth and Dailey had surgery to remove tumors on the kidney. And...
HC Wainwright Reaffirms Buy Rating for Exelixis (NASDAQ:EXEL)
ETF DAILY NEWS· 7 days agoHC Wainwright reaffirmed their buy rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research report sent to investors on Friday, Benzinga reports. Several other equities analysts ...